FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2605901750> ?p ?o ?g. }

• W2605901750 abstract "ABSTRACT The emergence and spread in Southeast Asia of Plasmodium falciparum resistance to artemisinin (ART) derivatives, the cornerstone of first-line artemisinin-based combination therapies (ACTs), underscore the urgent need to identify suitable replacement drugs. Discovery and development efforts have identified a series of ozonides with attractive chemical and pharmacological properties that are being touted as suitable replacements. Partial resistance to ART, defined as delayed parasite clearance in malaria patients treated with an ART derivative or an ACT, has been associated with mutations in the P. falciparum K13 gene. In light of reports showing that ART derivatives and ozonides share similar modes of action, we have investigated whether parasites expressing mutant K13 are cross-resistant to the ozonides OZ439 (artefenomel) and OZ227 (arterolane). This work used a panel of culture-adapted clinical isolates from Cambodia that were genetically edited to express variant forms of K13. Phenotypic analyses employed ring-stage survival assays (ring-stage survival assay from 0 to 3 h [RSA 0–3h ]), whose results have earlier been shown to correlate with parasite clearance rates in patients. Our results document cross-resistance between OZ277 and dihydroartemisinin (DHA), a semisynthetic derivative of ART, in parasites carrying the K13 mutations C580Y, R539T, and I543T. For OZ439, we observed cross-resistance only for parasites that carried the rare K13 I543T mutation, with no evidence of cross-resistance afforded by the prevalent C580Y mutation. Mixed-culture competition experiments with isogenic lines carrying modified K13 revealed variable growth deficits depending on the K13 mutation and parasite strain and provide a rationale for the broad dissemination of the fitness-neutral K13 C580Y mutation throughout strains currently circulating in Southeast Asia. IMPORTANCE ACTs have helped halve the malaria disease burden in recent years; however, emerging resistance to ART derivatives threatens to reverse this substantial progress. Resistance is driven primarily by mutations in the P. falciparum K13 gene. These mutations pose a threat to ozonides, touted as promising alternatives to ARTs that share a similar mode of action. We report that DHA was considerably more potent than OZ439 and OZ277 against ART-sensitive asexual blood-stage parasites cultured in vitro . We also document that mutant K13 significantly compromised the activity of the registered drug OZ277. In contrast, OZ439 remained effective against most parasite lines expressing mutant K13, with the exception of I543T that merits further monitoring in field-based OZ439 efficacy studies. K13 mutations differed considerably in their impact on parasite growth rates, in a strain-dependent context, with the most prevalent C580Y mutation being fitness neutral in recently culture-adapted strains from Cambodia, the epicenter of emerging ART resistance." @default.
• W2605901750 created "2017-04-28" @default.
• W2605901750 creator A5002449299 @default.
• W2605901750 creator A5006044672 @default.
• W2605901750 creator A5035473231 @default.
• W2605901750 creator A5040998252 @default.
• W2605901750 creator A5053946594 @default.
• W2605901750 creator A5071314941 @default.
• W2605901750 date "2017-05-03" @default.
• W2605901750 modified "2023-10-02" @default.
• W2605901750 title "<i>Plasmodium falciparum</i> K13 Mutations Differentially Impact Ozonide Susceptibility and Parasite Fitness <i>In Vitro</i>" @default.
• W2605901750 cites W1080779302 @default.
• W2605901750 cites W1714404487 @default.
• W2605901750 cites W1771852563 @default.
• W2605901750 cites W1886463152 @default.
• W2605901750 cites W1900102580 @default.
• W2605901750 cites W1969571661 @default.
• W2605901750 cites W1973603244 @default.
• W2605901750 cites W1993347313 @default.
• W2605901750 cites W1998878014 @default.
• W2605901750 cites W2014387796 @default.
• W2605901750 cites W2014392076 @default.
• W2605901750 cites W2019289617 @default.
• W2605901750 cites W2019758371 @default.
• W2605901750 cites W2040713555 @default.
• W2605901750 cites W2055730063 @default.
• W2605901750 cites W2068849886 @default.
• W2605901750 cites W2069378157 @default.
• W2605901750 cites W2074749191 @default.
• W2605901750 cites W2076029682 @default.
• W2605901750 cites W2081078606 @default.
• W2605901750 cites W2088387917 @default.
• W2605901750 cites W2102395543 @default.
• W2605901750 cites W2104700616 @default.
• W2605901750 cites W2108523891 @default.
• W2605901750 cites W2108981909 @default.
• W2605901750 cites W2124634096 @default.
• W2605901750 cites W2124779154 @default.
• W2605901750 cites W2125005430 @default.
• W2605901750 cites W2127174242 @default.
• W2605901750 cites W2129428401 @default.
• W2605901750 cites W2135155264 @default.
• W2605901750 cites W2136905362 @default.
• W2605901750 cites W2138584803 @default.
• W2605901750 cites W2143552714 @default.
• W2605901750 cites W2146428266 @default.
• W2605901750 cites W2156608799 @default.
• W2605901750 cites W2161311583 @default.
• W2605901750 cites W2168267873 @default.
• W2605901750 cites W2169329132 @default.
• W2605901750 cites W2171102256 @default.
• W2605901750 cites W2229864756 @default.
• W2605901750 cites W2273900672 @default.
• W2605901750 cites W2279630534 @default.
• W2605901750 cites W2290619588 @default.
• W2605901750 cites W2307970348 @default.
• W2605901750 cites W2347205592 @default.
• W2605901750 cites W2415187468 @default.
• W2605901750 cites W2467259677 @default.
• W2605901750 cites W2515855675 @default.
• W2605901750 cites W2516822342 @default.
• W2605901750 cites W2536811010 @default.
• W2605901750 cites W2547042202 @default.
• W2605901750 cites W2547295550 @default.
• W2605901750 cites W2553625841 @default.
• W2605901750 cites W2557591621 @default.
• W2605901750 cites W2563789790 @default.
• W2605901750 cites W2580065912 @default.
• W2605901750 doi "https://doi.org/10.1128/mbio.00172-17" @default.
• W2605901750 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5388803" @default.
• W2605901750 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28400526" @default.
• W2605901750 hasPublicationYear "2017" @default.
• W2605901750 type Work @default.
• W2605901750 sameAs 2605901750 @default.
• W2605901750 citedByCount "97" @default.
• W2605901750 countsByYear W26059017502017 @default.
• W2605901750 countsByYear W26059017502018 @default.
• W2605901750 countsByYear W26059017502019 @default.
• W2605901750 countsByYear W26059017502020 @default.
• W2605901750 countsByYear W26059017502021 @default.
• W2605901750 countsByYear W26059017502022 @default.
• W2605901750 countsByYear W26059017502023 @default.
• W2605901750 crossrefType "journal-article" @default.
• W2605901750 hasAuthorship W2605901750A5002449299 @default.
• W2605901750 hasAuthorship W2605901750A5006044672 @default.
• W2605901750 hasAuthorship W2605901750A5035473231 @default.
• W2605901750 hasAuthorship W2605901750A5040998252 @default.
• W2605901750 hasAuthorship W2605901750A5053946594 @default.
• W2605901750 hasAuthorship W2605901750A5071314941 @default.
• W2605901750 hasBestOaLocation W26059017501 @default.
• W2605901750 hasConcept C104317684 @default.
• W2605901750 hasConcept C136764020 @default.
• W2605901750 hasConcept C143065580 @default.
• W2605901750 hasConcept C159047783 @default.
• W2605901750 hasConcept C203014093 @default.
• W2605901750 hasConcept C2776120307 @default.
• W2605901750 hasConcept C2778048844 @default.
• W2605901750 hasConcept C2778371730 @default.
• W2605901750 hasConcept C2781160685 @default.
• W2605901750 hasConcept C41008148 @default.

• next